pharmacie et médicaments – Traitement Tofersen contre la maladie de Charcot

This written question concerns the Tofersen treatment for Amyotrophic Lateral Sclerosis (ALS), also known as Charcot's disease. It seeks information on the treatment's availability and accessibility within France. The question is directed towards French authorities, likely regarding national healthcare policies and drug reimbursement processes that affect patients with this rare neurological condition.